IRWD Share Price

Open 17.07 Change Price %
High 17.34 1 Day 0.05 0.29
Low 16.84 1 Week -0.41 -2.33
Close 17.15 1 Month 0.73 4.45
Volume 843203 1 Year 6.76 65.06
52 Week High 18.53
52 Week Low 9.06
IRWD Important Levels
Resistance 2 17.61
Resistance 1 17.42
Pivot 17.11
Support 1 16.88
Support 2 16.69
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
FTR 1.94 -8.06%
FTR 1.94 -8.06%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 26.47 1.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
LLEN 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.06 20.00%
FALC 0.36 16.13%
OTIV 1.70 15.65%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
VALV 0.02 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 4
As on 23rd Mar 2017 IRWD Share Price closed @ 17.15 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.33 & Buy for SHORT-TERM with Stoploss of 16.23 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for March
1st Target up-side 18.59
2nd Target up-side 19.78
3rd Target up-side 20.97
1st Target down-side 15.19
2nd Target down-side 14
3rd Target down-side 12.81
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.